FDA names permanent CDER director, boosts safety office

Share this article:
The FDA selected Gerald Dal Pan as director of the Office of Drug Safety in the Center for Drug Evaluation and Research (CDER). 
Dal Pan will report directly to the head of CDER, elevating the stature of the safety office to a level on par with the Office of New Drugs, which approves new medicines for sale, an FDA spokeswoman told MM&M.
Dal Pan joined the FDA in 2000. He most recently served as director, division of surveillance, research, and communication support, Office of Drug Safety in CDER, a position he has held since 2003. 
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.